Table 2.
Indications for treatment, ASFA 2019 categories, number of patients on treatment according to the decision about treatment, March –April 2020.
| ASFA 2019 | Emergent treatment | Continued | Reduced frequency | Stopped | |
|---|---|---|---|---|---|
| Therapeutic Plasma Exchange | |||||
| anti-P immunization in pregnancy | -- | 1 | |||
| Focal segmental glomerulosclerosis - Recurrent in kidney transplant | I | 1 | |||
| Hyperviscosity in hypergammaglobulinemia – symptomatic | I | 1 | |||
| Red cell alloimmunization in pregnancy | III | 2* | |||
| Myasthenia Gravis | II | 9 | |||
| Thrombotic microangiopathy | I | 1 | |||
| Neuromyelitis optica spectrum disorders | II | 2 | |||
| Graves orbitopathy | -- | 1 | |||
| Hypertriglyceridemic pancreatitis | III | 1 | |||
| Pemphigus vulgaris | III | 1 | 2 | ||
| Chronic inflammatory demyelinating polyradiculoneuropathy | I | 2 | 2 | ||
| Transplantation, renal – Antibody mediated rejection | I | 1 | |||
| Scleroderma/Systemic Sclerosis | III | 1 | 9 | ||
| Antiphospholipid syndrome during pregnancy | -- | 1 | |||
| Transplantation, renal, ABO incompatible– Desensitization (living donor) | I | 1 | |||
| Extracorporeal Photochemotherapy/Photopheresis | |||||
| Graft Versus Host Disease – Acute | II | 1§ | |||
| Graft Versus Host Disease – Chronic | II | 6 | |||
| Cutaneous T cell lymphoma – Erythrodermic | I | 3 | |||
| Atopic Dermatitis | III | 1 | |||
| Red Blood Cell Exchange | |||||
| Sickle cell disease – non acute (stroke prohylaxis/recurrent vaso-occlusive crisis) | I/II | 7 | |||
| AdsorptiveCytapheresis | |||||
| Hidradenitis suppurativa | -- | 4 | |||
| IBD | III | 1 | 1 | ||
| LipoproteinApheresis | |||||
| FH Oz | I | 2 | |||
| FH Hz | II | 2 | |||
| HyperLp(a) | II | 1 | 1 | ||
*
One of the 2 patients continued the scheduled treatment in another Center.
§
Treatment cycle considered completed at the beginning of the COVID-19 outbreak.